All entries for: ODDIFACT SAS

May 12, 2026

ODDIFACT SAS

Orphan Drug Designation

treatment of chronic graft-versus-host disease

Disease Area: Rare Diseases
March 24, 2026

ODDIFACT SAS

Orphan Drug Designation

treatment of myelin oligodendrocyte glycoprotein antibody-associated disease

Disease Area: Rare Diseases
February 2, 2026

ODDIFACT SAS

Orphan Drug Designation

treatment of neuromyelitis optica spectrum disorder

Disease Area: Rare Diseases
December 5, 2025

ODDIFACT SAS

Orphan Drug Designation

FDA orphan drug designation: treatment of Takayasu arteritis

Disease Area: Rare Diseases
November 19, 2025

ODDIFACT SAS

Orphan Drug Designation

FDA orphan drug designation: treatment of Behcet’s disease

Disease Area: Rare Diseases
November 9, 2025

ODDIFACT SAS

Orphan Drug Designation

FDA orphan drug designation: treatment of pyoderma gangrenosum

Disease Area: Rare Diseases
October 16, 2025

ODDIFACT SAS

Orphan Drug Designation

FDA orphan drug designation: treatment of bullous pemphigoid

Disease Area: Rare Diseases
July 18, 2025

ODDIFACT SAS

Orphan Drug Designation

FDA orphan drug designation: treatment of autoimmune hemolytic anemia

Disease Area: Rare Diseases
Scroll to Top